Talacotuzumab -Janssen Biotech

Drug Profile

Talacotuzumab -Janssen Biotech

Alternative Names: CSL 362AML; CSL-362; IL-13 MAb - CSL; JNJ 473; JNJ 56022473

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CSL
  • Developer CSL; Janssen Biotech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin-3-receptor-alpha-subunit-antagonists; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Myelodysplastic syndromes
  • Preclinical Systemic lupus erythematosus

Most Recent Events

  • 04 Dec 2017 Janssen terminates a phase II trial in Acute myeloid leukaemia and Myelodysplastic syndromes (Monotherapy, Second-line therapy or greater) in Germany and France (IV) (NCT02992860)
  • 27 Nov 2017 Janssen Research & Development withdraws a phase Ib trial for Systemic lupus erythematosus (Treatment-experienced) in Germany, prior to enrolment (SC) (NCT02920424)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Monotherapy, Second-line therapy or greater) in Australia (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top